Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

• Brian D. Lehmann ,

  * E-mail: brian.d.lehmann@vanderbilt.edu (BDL); j.pietenpol@vanderbilt.edu (JAP)

  Affiliation Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, United States of America

  ⨯
• Bojana Jovanović,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, United States of America

  ⨯
• Xi Chen,

  Affiliations Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, United States of America, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States of America

  ⨯
• Monica V. Estrada,

  Affiliation Department of Medicine, Breast Cancer Research Program, Vanderbilt University, Nashville, Tennessee, United States of America

  ⨯
• Kimberly N. Johnson,

  Affiliation Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, United States of America

  ⨯
• Yu Shyr,

  Affiliation Center for Quantitative Sciences, Division of Cancer Biostatistics, Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, United States of America

  ⨯
• Harold L. Moses,

  Affiliation Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, United States of America

  ⨯
• Melinda E. Sanders,

  Affiliation Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, United States of America

  ⨯
• Jennifer A. Pietenpol

  * E-mail: brian.d.lehmann@vanderbilt.edu (BDL); j.pietenpol@vanderbilt.edu (JAP)

  Affiliations Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, United States of America, Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, United States of America

  ⨯